Last reviewed · How we verify

Heavy Bupivacaine — Competitive Intelligence Brief

Heavy Bupivacaine (Heavy Bupivacaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide). Area: Anesthesia.

marketed Local anesthetic (amide) Voltage-gated sodium channels Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Heavy Bupivacaine (Heavy Bupivacaine) — Diskapi Yildirim Beyazit Education and Research Hospital. Heavy bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Heavy Bupivacaine TARGET Heavy Bupivacaine Diskapi Yildirim Beyazit Education and Research Hospital marketed Local anesthetic (amide) Voltage-gated sodium channels
ESL ESL Bial - Portela C S.A. marketed Voltage-gated sodium channel blocker; anticonvulsant Voltage-gated sodium channels (Nav)
Exparel + Bupivacaine Exparel + Bupivacaine Pacira Pharmaceuticals, Inc marketed Local anesthetic (liposomal formulation) Voltage-gated sodium channels
carbamazepine ER (Equetro) carbamazepine ER (Equetro) Massachusetts General Hospital marketed Anticonvulsant; mood stabilizer Voltage-gated sodium channels
Exparel TAP + multi-modal pain regimen Exparel TAP + multi-modal pain regimen Pacira Pharmaceuticals, Inc marketed Local anesthetic (liposomal formulation) Voltage-gated sodium channels
Suzetrigine (SUZ) Suzetrigine (SUZ) Vertex Pharmaceuticals Incorporated marketed Selective sodium channel inhibitor Voltage-gated sodium channels (Nav)
local infiltration of liposomal bupivacaine local infiltration of liposomal bupivacaine TriHealth Inc. marketed Local anesthetic (amide class) Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide) class)

  1. Poznan University of Medical Sciences · 4 drugs in this class
  2. Nantes University Hospital · 3 drugs in this class
  3. Bozyaka Training and Research Hospital · 2 drugs in this class
  4. ASST Gaetano Pini-CTO · 2 drugs in this class
  5. Centre Hospitalier Universitaire de Nīmes · 1 drug in this class
  6. Chiang Mai University · 1 drug in this class
  7. Beijing Tiantan Hospital · 1 drug in this class
  8. Complejo Hospitalario Universitario de Granada · 1 drug in this class
  9. Ciusss de L'Est de l'Île de Montréal · 1 drug in this class
  10. China Medical University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Heavy Bupivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/heavy-bupivacaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: